Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Q4 2024 Earnings Call Transcript March 3, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is ...

Wet AMD remains the leading cause of vision loss in the elderly, impacting about 3.5 million people in the US and Europe alone. The unmet medical need in wet AMD is significant, with many patients ...

We remain committed to bringing an ophthalmic bevacizumab to market in the United States and providing retina patients suffering from wet AMD with a much needed treatment option that has the potential ...

Zervimesine is an investigational oral, once-daily pill being developed for the treatment of CNS diseases, including ...

Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...

New anti–vascular endothelial growth factor (VEGF) therapies are improving retinal disease management by providing patients ...

The cause of age-related macular degeneration can be varied and symptoms are often not recognized immediately, according to ...

Wet AMD is the leading cause of vision loss in the elderly, affecting around three million people in the US and Europe and driving a retinal disease market that is worth upwards of $18 billion a year.

The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular ...

COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet ... retinal diseases, including wet age-related macular degeneration (wet AMD), We recently ...